On October 6th New England Compounding Pharmacy (NECC), announced a recall of all of its products that were compounded at and distributed from its facility in Framingham, Massachusetts. One of those products (preservative-free
MCH’s highest priority is the safety of our patients and we are fully and proactively engaged in this effort. Beyond those medications directly linked to cases of meningitis, the FDA, on October 15th, advised hospitals across the US to contact patients that receivedany injectable drug from the NECC produced after May 21st, 2012 to see if they have experienced any unusual symptoms or reactions. MCH patients who have received any of these injectable drugs from the NECC will be contacted and given specific instructions to assist us in gathering patient information as we assist the FDA in their data collection. To date, the FDA has not been able to confirm any additional cases of infection have been caused by NECC products beyond the original product directly linked to the meningitis outbreak. Again, the product linked to meningitis from the NECC has never been used here at MCH.